Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $63.49
    +0.13 (+0.21%)

    Market Cap: $5.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    PTC Therapeutics Inc (PTCT) Financials: Revenue, Profit and Cash Flow

    Updated Jul 30, 2026. Financial statements from company filings, amounts in US dollars.

    PTC Therapeutics reported revenue of $1.73B for the fiscal year ended Dec 31, 2025, up 114.5% from the year before. That year, net income was $682.64M with a net margin of 39.4%, operating cash flow was $711.20M and free cash flow was $702.34M. The quarter ended Jun 30, 2026 had revenue of $360.52M and net income of $83.50M.

    Revenue and Margins

    The operating margin was 50.1% in the fiscal year ended Dec 2025, the highest of the 8 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $82.70M, a compound annual rate of 40.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.73B+114.5%100.0%50.1%39.4%
    Dec 2024$806.78M-14.0%92.9%-37.5%-45.0%
    Dec 2023$937.82M+34.2%100.0%-46.9%-66.8%
    Dec 2022$698.80M+29.7%93.6%-64.0%-80.0%
    Dec 2021$538.59M+41.4%94.0%-69.5%-97.3%
    Dec 2020$380.77M+24.0%95.0%-113.4%-115.1%
    Dec 2019$306.98M+16.0%96.0%-78.6%-82.0%
    Dec 2018$264.73M+36.2%95.2%-43.7%-48.4%
    Dec 2017$194.39M+135.0%97.6%-33.1%-40.6%
    Dec 2016$82.70MN/A100.0%-159.7%-171.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.73B$806.78M$937.82M$698.80M$538.59M$380.77M$306.98M$264.73M$194.39M$82.70M
    Cost of revenue$0$57.40M$0$44.68M$32.33M$18.94M$12.13M$12.67M$4.58M$0
    Gross profit$1.73B$749.38M$937.82M$654.12M$506.26M$361.82M$294.85M$252.06M$189.81M$82.70M
    Research and development$455.25M$534.48M$666.56M$651.50M$540.68M$477.64M$257.45M$171.98M$117.46M$117.63M
    Operating income$866.93M-$302.57M-$439.50M-$447.41M-$374.44M-$431.77M-$241.16M-$115.69M-$64.29M-$132.06M
    Net income$682.64M-$363.30M-$626.60M-$559.02M-$523.90M-$438.16M-$251.58M-$128.08M-$79.00M-$142.11M
    EBITDA$870.86M-$231.69M-$193.11M-$364.17M-$361.04M-$260.28M-$196.48M-$89.38M-$46.92M-$127.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$360.52M$272.55M$164.68M$211.01M$178.88M$1.18B$213.17M$196.79M$186.70M$210.12M$307.06M$196.58M
    Gross profit$340.60M$244.52M$188.96M$211.01M$167.46M$1.18B$186.04M$196.79M$171.18M$195.38M$343.42M$187.08M
    Operating income$148.98M$44.96M-$71.35M$3.02M-$34.96M$970.23M-$162.39M-$54.51M-$40.22M-$45.45M$5.82M-$118.16M
    Net income$83.50M-$2.81M-$134.97M$15.90M-$64.85M$866.56M-$65.89M-$106.65M-$99.18M-$91.58M-$155.79M-$132.97M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $286.63M by $698.02M. Shareholder equity was negative, at -$205.31M, as total liabilities of $3.10B exceeded total assets of $2.90B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.90B$1.71B$1.90B$1.71B$1.94B$2.21B$1.62B$1.12B$391.65M$269.35M
    Current assets$2.27B$1.37B$1.22B$693.78M$954.37M$1.23B$779.28M$320.86M$249.06M$261.29M
    Cash and equivalents$984.65M$779.71M$594.00M$279.83M$189.72M$208.81M$288.03M$227.59M$111.79M$58.32M
    Total liabilities$3.10B$2.80B$2.71B$2.05B$1.94B$1.73B$1.03B$768.50M$235.22M$149.76M
    Short-term debt$286.63M$0$210.32M$84.52M$149.54M$0$20.00M$11.67M$0$40.87M
    Long-term debt$0$285.41M$284.21M$571.72M$281.89M$309.14M$293.86M$141.35M$144.97M$98.22M
    Shareholder equity-$205.31M-$1.10B-$818.55M-$347.09M$1.44M$481.98M$594.33M$350.73M$156.44M$119.58M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$3.25B$2.87B$2.91B$2.64B$2.63B$2.66B$1.71B$1.84B$1.92B$1.79B$1.90B$1.26B
    Total liabilities$3.42B$3.05B$3.12B$2.80B$2.84B$2.84B$2.80B$2.90B$2.90B$2.68B$2.71B$1.93B
    Cash and equivalents$1.05B$833.99M$984.65M$672.62M$1.02B$1.48B$779.71M$526.00M$654.78M$548.36M$594.00M$165.16M
    Shareholder equity-$165.36M-$180.47M-$205.31M-$155.76M-$206.55M-$185.76M-$1.10B-$1.05B-$980.18M-$893.92M-$818.55M-$670.81M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.8% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$711.20M-$107.69M-$158.42M-$356.65M-$251.33M-$194.07M-$98.64M-$27.64M-$10.06M-$103.57M
    Capital expenditures$8.86M$6.50M$28.44M$32.02M$28.21M$17.84M$13.76M$7.10M$3.10M$1.78M
    Free cash flow$702.34M-$114.19M-$186.86M-$388.67M-$279.55M-$211.91M-$112.40M-$34.74M-$13.16M-$105.34M
    Investing cash flow-$861.98M$44.18M-$176.74M$290.18M$219.18M-$561.55M-$387.24M-$42.61M$13.12M$104.48M
    Financing cash flow$331.09M$255.87M$646.40M$167.95M$20.88M$668.72M$613.21M$131.57M$44.22M$968.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$129.11M-$59.04M-$34.27M-$66.30M-$58.33M$870.10M-$30.00M-$76.99M-$71.45M$70.76M-$100.29M-$14.52M
    Capital expenditures$2.19M$1.20M$2.37M$3.44M$1.25M$1.72M$3.77M$522.00K$7.38M$9.59M$5.57M$6.36M
    Free cash flow$126.92M-$60.24M-$36.65M-$69.75M-$59.58M$868.38M-$33.77M-$77.51M-$78.83M$61.17M-$105.85M-$20.88M
    Last 12 quarters

    Frequently Asked Questions About PTCT

    What is PTC Therapeutics' annual revenue?

    PTC Therapeutics reported revenue of $1.73B for the fiscal year ended Dec 31, 2025.

    How fast is PTC Therapeutics' revenue growing?

    Revenue was up 114.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.3%.

    Is PTC Therapeutics profitable?

    Yes. PTC Therapeutics reported net income of $682.64M for the fiscal year ended Dec 31, 2025, with a net margin of 39.4%.

    How much free cash flow does PTCT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $711.20M minus capital expenditures of $8.86M produced free cash flow of $702.34M.

    How much debt does PTC Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $286.63M and cash and equivalents of $984.65M.